The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Diane DamotteSarah WarrenJennifer ArrondeauPascaline Boudou-RouquetteAudrey Mansuet-LupoJérôme BitonHanane OuakrimMarco AlifanoClaire GervaisAudrey BellesoeurNora KramkimelCamille TlemsaniBarbara BurroniAngéline DucheFranck LetourneurHan SiRebecca HalpinTodd CreasyRonald HerbstXing RenPascale MorelAlessandra CesanoFrançois GoldwasserKaren LeroyPublished in: Journal of translational medicine (2019)
These results indicate that validated gene expression assay measuring the level of tumor microenvironment inflammation such as TIS, are accurate and independent predictive biomarkers and can be easily implemented in the clinical practice.